Hadasit Bio-Holdings

Press Releases

KAHR expands and strengthens its intellectual property

Feb. 4, 2013

KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101

KAHR expands and strengthens its intellectual property with patent for improving cancer treatment

KAHR Medical Ltd. (“KAHR”), was granted a U.S. patent approval (U.S. Patent No. 8329657).

This patent approval follows other patents already received in the U.S., Europe, Japan and Israel, protecting different combinations of KAHR’s 'Signal Converting Proteins (SCPs)', which are bi-functional chimeric proteins with synergistic effects that improve the efficiency of pharmaceutical treatments. The newly issued patent protects one of KAHR’s products in development, KAHR- 101, which has been shown to be effective in the treatment of various cancers, arthritis and multiple sclerosis in animal models.

Ophir Shahaf, CEO of Hadasit Bio-Holdings, stated, “KAHR Medical develops ground-breaking products and we are constantly working to strengthen the company's intellectual property. The company uses a novel technology by which two therapeutic pathways can be simultaneously stimulated by a single protein drug in a synergistic manner, optimizing the care provided to patients. The completion of a recent fundraising round a few months ago will allow for further development and advancement of KAHR’s drugs. We believe that in the coming year our portfolio companies will continue to present considerable clinical and business developments increasing their value as well as ours.”

 
 

Press Releases Archive